Atom Investors LP Has $2.40 Million Position in Enfusion, Inc. (NYSE:ENFN)

Atom Investors LP boosted its position in shares of Enfusion, Inc. (NYSE:ENFN) by 2.4% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 252,978 shares of the company’s stock after buying an additional 5,858 shares during the quarter. Atom Investors LP’s holdings in Enfusion were worth $2,401,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Harbor Capital Advisors Inc. increased its stake in shares of Enfusion by 12.4% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock valued at $113,000 after buying an additional 1,315 shares during the period. Azora Capital LP boosted its holdings in Enfusion by 6.8% in the third quarter. Azora Capital LP now owns 29,827 shares of the company’s stock valued at $283,000 after acquiring an additional 1,890 shares during the last quarter. 272 Capital LP increased its position in Enfusion by 1.5% in the second quarter. 272 Capital LP now owns 139,180 shares of the company’s stock worth $1,186,000 after purchasing an additional 2,000 shares during the period. California State Teachers Retirement System raised its holdings in Enfusion by 11.0% during the 1st quarter. California State Teachers Retirement System now owns 36,002 shares of the company’s stock worth $333,000 after purchasing an additional 3,556 shares during the last quarter. Finally, The Manufacturers Life Insurance Company lifted its position in Enfusion by 27.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,562 shares of the company’s stock valued at $167,000 after purchasing an additional 4,239 shares during the period. Institutional investors and hedge funds own 81.05% of the company’s stock.

Enfusion Trading Up 2.0 %

Shares of NYSE ENFN opened at $10.14 on Tuesday. Enfusion, Inc. has a 1 year low of $7.52 and a 1 year high of $10.40. The firm’s 50-day moving average is $9.33 and its 200-day moving average is $8.89. The firm has a market capitalization of $1.30 billion, a PE ratio of 253.50, a price-to-earnings-growth ratio of 3.72 and a beta of 0.93.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.